Together, our data demonstrated that Neogenin interacts with Merlin to inhibit tumor malignancy by obstructing EMT progress, and the lack of Neogenin/Merlin is associated with the poorest prognosis in CRC and glioma patients. The gene discussed is NEO1; the disease is glioma.